Cadence neurology news

Cadence said in its 4Q11 earnings that during the quarter it restructured and reduced headcount by 17 (7%) to 227 to focus resources on commercialization of Ofirmev IV acetaminophen. The cuts came primarily from development and general administrative areas. The company, which disclosed the news last November, said it expects the restructuring will reduce annual expenditures by about $3.8 million. At Dec. 31, 2011, Cadence had $127.2 million in cash and a 12-month operating loss of $88.7 million. ...